TTK HealthcareBOM:507747 +1.47%77 ROA % is 6.55% as of Mar. 2026, which is 6% above its 10-year median of 6.17. GuruFocus rates BOM:507747 with a GF Score™ of 77/100 and a GF Value™ of ₹1,452.52 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 1,003 Drug Manufacturers companies, TTK Healthcare ranks better than 61.81% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. TTK Healthcare's annualizedNet Income for the quarter that ended in Mar. 2026 was ₹870 Mil.
TTK Healthcare's average Total Assets over the quarter that ended in Mar. 2026 was ₹13,287 Mil. Therefore, TTK Healthcare's annualized ROA % for the quarter that ended in Mar. 2026 was 6.55%.
The historical rank and industry rank for TTK Healthcare's ROA % or its related term are showing as below:
BOM:507747'
s ROA % Range Over the Past 10 Years
Min: 2.91 Med: 6.17 Max: 74.01
Current: 5.05
During the past 13 years, TTK Healthcare's highest ROA % was 74.01%. The lowest was 2.91%. And the median was 6.17%.
BOM:507747's ROA % is ranked better than 61.81% of 1003
companies
in the Drug Manufacturers industry
Industry Median: 2.72
vs BOM:507747: 5.05
TTK Healthcare (BOM:507747) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
TTK Healthcare ROA % Related Terms
TTK Healthcare ROA % Historical Data
* Premium members only.
The historical data trend for TTK Healthcare's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, TTK Healthcare's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TTK Healthcare ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, TTK Healthcare's ROA % distribution charts can be found below:
* The bar in red indicates where TTK Healthcare's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
TTK Healthcare (BOM:507747) has a ROA % of 6.55% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on TTK Healthcare and its competitors. This is near median its historical median of 6.17. Over the past decade, TTK Healthcare's ROA % has ranged from 2.91 to 74.01. According to the industry distribution chart, TTK Healthcare ranks #383 out of 1003 companies in the Drug Manufacturers industry, placing it in the top 38.2%.
Is TTK Healthcare's ROA % too high?
TTK Healthcare's current ROA % of 6.55% is near median its 10-year median of 6.17. Over the past 10 years, this metric has ranged from a low of 2.91 to a high of 74.01. The Drug Manufacturers industry median ROA % is 2.72. TTK Healthcare's value of 6.55% is 140.8% above this industry median. Based on the distribution chart, TTK Healthcare ranks #383 out of 1003 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, TTK Healthcare has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TTK Healthcare's ROA % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, TTK Healthcare ranks #383 out of 1003 companies for ROA %. This puts TTK Healthcare in the upper half of its industry. The industry median ROA % is 2.72. TTK Healthcare's value of 6.55% is 140.8% above this benchmark. Historically, TTK Healthcare's own ROA % has ranged from 2.91 to 74.01 over the past decade. While the company's 10-year median is 6.17 vs. the industry median of 2.72, TTK Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.72, based on 1,003 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TTK Healthcare's current ROA % of 6.55% is 140.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on TTK Healthcare and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TTK Healthcare's current ROA % is 6.55%, which is near median its own 10-year median of 6.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TTK Healthcare stock overvalued right now?
Based on GuruFocus' analysis, TTK Healthcare (BOM:507747) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹1,452.52, compared to a current price of ₹920.00 — trading 36.7% below its estimated fair value. The current ROA % is 6.55%, which is near median its 10-year median of 6.17 and 140.8% above the Drug Manufacturers industry median of 2.72. TTK Healthcare's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For TTK Healthcare (BOM:507747), the current ROA % is 6.55% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TTK Healthcare (BOM:507747) Overvalued in 2026?
Based on GuruFocus' analysis, TTK Healthcare stock appears to be undervalued.
The current stock price of ₹920.00 is trading 36.7% below its estimated GF Value™ of ₹1,452.52.
GuruFocus considers TTK Healthcare to be Significantly Undervalued.
Key valuation signals for BOM:507747:
ROA %: 6.55% (near median its 10-year median of 6.17)
GF Value™: ₹1,452.52 vs. price of ₹920.00 (36.7% below fair value)
Industry Position: 140.8% above the Drug Manufacturers median (#383 of 1003)
No single metric tells the full story. See the BOM:507747 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TTK Healthcare Ltd is an Indian pharmaceutical company. The company's operating segment includes Animal Welfare, Consumer Products, Medical Devices, Protective Devices, Foods Division, and Others. Its Animal Welfare segment includes products for both Human and Veterinary use. The Consumer Products comprises of marketing and distribution of Woodwards's Gripe Water, EVA Range of Cosmetics, Good Home range of Scrubbers, Air Fresheners and others. Protective Devices comprises of manufacturing and marketing of Male Contraceptives and other allied products. It generates maximum revenue from the Pharmaceuticals segment. Geographically, it derives a majority of revenue from India.
77GF Score
Get the complete analysis for BOM:507747
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:507747 has been successfully added to your 
